Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥175.00 - ¥444.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)152.98K
Market Cap
¥7.71B
Enterprise Value¥6.74B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.69
Shares Outstanding39,539,818
10 Day Avg. Volume202,820
30 Day Avg. Volume152,983
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regenerative Medicine PlatformA focused regenerative-medicine platform gives CellSeed a coherent long-term business direction spanning therapies, cell culture, and cell-sheet engineering. This specialization can support continued development of multiple products or services from related technical capabilities over the next several quarters.
Healthy Gross MarginsConsistently healthy gross margins indicate that the company’s offerings have generated meaningful gross profit relative to revenue, despite the current scale. If revenue recovers, this underlying gross-profit profile could provide a foundation for operating leverage and improved profitability.
Conservative LeverageLow leverage limits the immediate burden of debt service and preserves some financial flexibility while CellSeed develops its regenerative-medicine activities. Compared with a highly leveraged balance sheet, this provides more room to manage losses and consider funding needs over the medium term.
Bears Say
Sharp Revenue DeteriorationThe abrupt revenue decline shows that recent commercial momentum has weakened materially, making the company’s near-term revenue base less dependable. Sustained contraction would reduce the scale available to absorb fixed costs and could delay the transition from development activity to a self-supporting business.
Very Large Operating LossesLarge and widening losses indicate that CellSeed’s current cost base is far above the revenue generated by the business. Even with healthy gross margins, this gap can consume capital for an extended period and makes a durable path to profitability dependent on substantial revenue improvement or cost reduction.
Persistent Cash Burn And Funding RiskPersistent operating and free-cash-flow deficits show that the business has not demonstrated the ability to fund operations internally. Continued cash burn increases reliance on external financing, while declining equity and potential dilution risk could constrain long-term shareholder value if losses persist.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥175.00 and its highest was ¥444.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥7.71B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is Nov 13, 2026 which is in 14 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Aug 13, 2026. The company reported -¥8.69 earnings per share for the quarter.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 39,539,818 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥8.69 in its last earnings report. Following the earnings report the stock price went down -0.433%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―